Rhythm Pharmaceuticals logo
RYTMRhythm Pharmaceuticals
Trade RYTM now
Rhythm Pharmaceuticals primary media

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals (NASDAQ:RYTM) focuses on developing and commercializing therapies for people living with rare genetic diseases of obesity. Primarily engaging in the discovery, research, and development of innovative pharmaceuticals, Rhythm aims to address the unmet needs of patients suffering from these complex conditions. The company's leading project involves the peptide-1 (MC4R) agonist, setmelanotide, targeted at treating a spectrum of rare genetic disorders that contribute to obesity. Through its dedicated efforts, Rhythm seeks not only to advance its pipeline of transformative treatments but also to enhance understanding and management of rare obesity disorders, ultimately striving to improve patients' lives worldwide.

What is RYTM known for?

Snapshot

Public US
Ownership
2008
Year founded
244
Employees
Boston, United States
Head office
1 of 5
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
Boston, US

Products and/or services of Rhythm Pharmaceuticals

  • Setmelanotide (IMCIVREE), a treatment for obesity caused by rare genetic disorders by activating the MC4R pathway.
  • Clinical development of setmelanotide for additional rare genetic disorders of obesity, aiming to expand its indications.
  • Research on next-generation MC4R agonists designed to treat a broader range of disorders.
  • Collaborations for enhancing genetic testing and identification for early diagnosis of rare genetic disorders of obesity.
  • Programs to support and educate healthcare professionals on the diagnosis and treatment of rare genetic disorders of obesity.
  • Patient advocacy and support programs aimed at improving awareness and access to care for those with rare genetic disorders of obesity.

Rhythm Pharmaceuticals executive team

  • Dr. David P. Meeker M.D.Chairman, President & CEO
  • Mr. Hunter C. Smith M.B.A.CFO & Treasurer
  • Mr. Joseph ShulmanChief Technical Officer
  • Mr. Yann MazabraudExecutive VP & Head of International
  • Ms. Jennifer LeeExecutive VP & Head of North America
  • Mr. Christopher P. GermanCorporate Controller & Principal Accounting Officer
  • Dr. Alastair Garfield Ph.D.Chief Scientific Officer
  • Mr. David ConnollyHead of Investor Relations & Corporate Communications
  • Mr. Jim FlahertySenior VP & General Counsel
  • Ms. Sarah RyanVice President of Sales & Marketing

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.